Cell & Gene Therapy News
Children’s Hospital of Philadelphia Secures Five-year, up to $38.9 Million ARPA-H Award to Advance Personalized Gene Editing Therapies
CHOP announced today that it has been awarded a five-year up to $38.9 million award from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE program to support the advancement of personalized gene therapy.
Department of Health – Abu Dhabi and Children’s Hospital of Philadelphia Launch Strategic Collaboration to Advance Gene Editing Capabilities for Rare Diseases
DoH Abu Dhabi and CHOP signed an MoU at BIO in San Diego to collaborate on advancing gene-editing capabilities and speeding innovation in rare-disease care in UAE at scale
American Society of Gene and Cell Therapy Awards Beverly L. Davidson, PhD, Outstanding Achievement Award
CHOP is pleased to announce that Beverly L. Davidson, PhD, Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Chief Scientific Strategy Officer at CHOP, and Professor of Pathology and Laboratory Medicine at Penn Medicine, received the American Society of Gene and Cell Therapy (ASGCT) Outstanding Achievement Award, the society’s highest honor.
The National Academy of Medicine Names Lindsey A. George, MD, to its 2026 class of Emerging Leaders in Health and Medicine
Children’s Hospital of Philadelphia (CHOP) announced today that the National Academy of Medicine (NAM) named Lindsey A. George, M.D., Director of Clinical In Vivo Gene Therapy, and an attending physician in the Division of Hematology at CHOP, as a member of its 2026 class of Emerging Leaders in Health and Medicine (ELHM) scholars.
Analysis of Brain Tumor Following AAV Gene Therapy Identifies Vector Integration and Reinforces Importance of Long-Term Monitoring
CHOP researchers reported today in the New England Journal of Medicine about a rare but noteworthy outcome in a child treated with an adeno-associated virus (AAV) gene therapy for severe mucopolysaccharidosis type I (MPS I). MPS I, a lysosomal storage disorder also known as Hurler Syndrome, is characterized by an abnormal build-up of various toxic materials, called glycosaminoglycans (GAGs) in the body's cells.
Gene Editing Innovators Receive 2026 Catalyst Award at American Society of Gene & Cell Therapy’s Annual Conference
Children’s Hospital of Philadelphia (CHOP), Danaher Corporation, the Innovative Genomics Institute (IGI), and Penn Medicine celebrate members of their teams as the 2026 recipients of the American Society of Gene & Cell Therapy’s (ASGCT) Catalyst Award.
Children’s Hospital of Philadelphia Physicians to Present at American Society of Gene and Cell Therapy (ASGCT)
Children’s Hospital of Philadelphia (CHOP) today announced that CHOP physicians conducting genetic research will present new and updated data at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Boston, Massachusetts, May 11–15, 2026.
Children’s Hospital of Philadelphia Celebrates Pioneering Gene Therapy Contributions at 12th Annual Breakthrough Prize Awards
Children’s Hospital of Philadelphia announced Katherine High, MD; Jean Bennett, MD, PhD; and Albert Maguire, MD received the Breakthrough Prize for the first FDA‑approved gene therapy.
Children’s Hospital of Philadelphia, Penn Medicine team awarded Breakthrough Prize for developing gene therapy for inherited blindness
Drs. Katherine High, Jean Bennett and Albert Maguire honored for trailblazing work on the first FDA-approved gene therapy for an inherited condition
Researchers Behind World’s First Patient-Tailored CRISPR Gene Editing Therapy Named to TIME100 List of the 100 Most Influential People in the World
Drs. Rebecca Ahrens-Nicklas, MD and Kiran Musunuru were named to the 2026 TIME100 Most Influential People in the World list.